Ultra Market Research | United States Bacterial Pneumonia Market
United States Bacterial Pneumonia Market
Report ID : 1115
Category : United-States(US)
No Of Pages : 156
Published on: June 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The US Bacterial Pneumonia Market involves the diagnosis, treatment, and prevention of bacterial pneumonia, a major cause of respiratory infections. The common pathogens are Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. There has been significant progress in diagnostic technologies, including molecular testing and point-of-care testing devices, which enhance the speed and accuracy of pneumonia diagnosis. Also, the growing prevalence of antibiotic-resistant bacterial strains is challenging in the treatment of bacterial pneumonia. Preventive interventions and vaccination campaigns are important in lowering the occurrence of bacterial pneumonia. The increasing elderly population, who are more likely to suffer from bacterial pneumonia caused by physiological changes in the immune system and underlying conditions with age, also impacts the market. The U.S. market for the treatment of bacterial pneumonia is expected to expand considerably, spurred by these and the continuing evolution of new therapeutics and vaccines.
Segmentation
Segment 1: Drug Type
Antibiotics
Beta-lactams
Macrolides
Fluoroquinolones
Others
Vaccines
Conjugate Vaccines
Polysaccharide Vaccines
Others
Others
Segment 2: Route of Administration
Oral
Tablets
Capsules
Others
Intravenous
Injection
Infusion
Others
Others
Segment 3: Age Group
Pediatric
Infants
Children
Adolescents
Adult
Young Adults
Middle-aged Adults
Elderly Adults
Others
Segment 4: Distribution Channel
Hospital Pharmacies
Inpatient
Outpatient
Retail Pharmacies
Chain Pharmacies
Independent Pharmacies
Online Pharmacies
E-commerce Platforms
Telemedicine Services
Others
List of Market Players
Pfizer Inc. (USA)
Merck & Co., Inc. (USA)
AstraZeneca PLC (UK)
Novartis AG (Switzerland)
AbbVie Inc. (USA)
Sanofi S.A. (France)
Basilea Pharmaceutica Ltd. (Switzerland)
Innoviva Specialty Therapeutics (USA)
Teva Pharmaceutical Industries Ltd. (Israel)
Lupin Pharmaceuticals, Inc. (India)
Sumitomo Pharma Co., Ltd. (Japan)
Wockhardt Ltd. (India)
Clarametyx Biosciences (USA)
Aridis Pharmaceuticals (USA)
Eagle Pharmaceuticals, Inc. (USA)
Drivers
The United States Bacterial Pneumonia Market is driven by a number of key drivers. The disease burden of bacterial pneumonia is high, and therefore, the need for effective diagnostics, treatments, and prevention measures is high. The growing trend of antibiotic-resistant bacteria, such as multidrug-resistant pneumonia pathogens, reduces the efficacy of conventional antibiotics, fueling the need for new antimicrobial drugs and alternative modes of therapy. The increasing elderly population is at increased risk for bacterial pneumonia because of the changes in the immune system due to age and comorbid conditions, making it necessary to have age-specific management and treatment plans. Improved diagnostic technologies, including molecular diagnostics and point-of-care technology, have enhanced the speed and accuracy of diagnosis for pneumonia, leading to timely appropriate treatment. In addition, preventive measures and vaccination programs help in lowering the occurrence of bacterial pneumonia, hence boosting market growth.
Restraints
Even with the growth of the market, some challenges hinder its progress. Antibiotic resistance is still a major barrier as the development and dissemination of multidrug-resistant strains restrict treatment and complicate management. Restricted access to medical care, especially in rural areas and underserved territories, represents a deterrent to early diagnosis and treatment and, hence, worse patient outcomes. The expense of newer diagnostic equipment and innovative therapeutics could limit their implementation, particularly in resource-limited environments. Furthermore, the effect of antibiotic stewardship interventions, which reduce the usage of unnecessary antibiotics, could influence the demand for particular treatments and complicate market dynamics.
Opportunity
Opportunity
The United States Bacterial Pneumonia Market offers huge potential for growth. The creation of new antibiotics and other treatments to fight antibiotic-resistant bacterial infections is a priority, providing potential means for market growth. Enhancement of vaccination programs, particularly for high-risk groups including the elderly and immunocompromised, can help decrease the occurrence of bacterial pneumonia and related healthcare expenditure. Technological advancements in diagnostic equipment, such as rapid molecular diagnostics and point-of-care devices, facilitate early diagnosis and targeted treatment regimens, enhancing patient outcomes. In addition, public health campaigns focusing on elevating awareness and availability of pneumonia prevention and treatment can further propel market expansion.
Trend
One of the prominent trends in the United States Bacterial Pneumonia Market is the movement towards precision medicine and targeted treatment protocols. This includes the adaptation of treatment protocols to the individual bacterial strain responsible for the infection and taking into account the antibiotic resistance profile of the strain. Advances in diagnostic technology, including the use of rapid molecular tests, allow identification of the exact bacterial pathogen so that clinicians may select the best antibiotic therapy in a timely manner. This focused strategy not only enhances patient outcomes but also stops antibiotic resistance by minimizing the overuse of broad-spectrum antibiotics. Moreover, personalized treatment strategies take patient-specific factors such as age, systemic conditions, and past medical history into account, thereby ensuring that patients are given the best and safest possible treatment.
Approved Products
Zevtera (ceftobiprole)
Nuzyra (omadacycline)
Emblaveo (aztreonam/avibactam)
Xacduro (sulbactam/durlobactam)
VAX-31 (Vaxcyte)
Capvaxive (Merck)
Prevnar 20 (Pfizer)
Vaxneuvance (Merck)
Pneumovax 23 (Merck)
Pneumovax 13 (Pfizer)
Key Target Audience
Healthcare Providers
Pharmaceutical Companies
Biotechnology Firms
Medical Researchers
Regulatory Agencies
Hospitals and Clinics
Diagnostic Laboratories
Insurance Companies
Public Health Organizations
Investors and Analysts
The market is projected to grow significantly, driven by factors such as the high disease burden, increasing antibiotic resistance, and the growing geriatric population.
Key players include Pfizer Inc., Merck & Co., Inc., AbbVie Inc., and Basilea Pharmaceutica Ltd.
High disease burden, increasing antibiotic resistance, growing geriatric population, and advancements in diagnostic technologies are key drivers.
Antibiotic resistance, limited access to healthcare, high treatment costs, and the impact of antibiotic stewardship measures pose challenges.
Development of novel antibiotics, expansion of vaccination programs, advancements in diagnostic technologies, and public health initiatives offer growth opportunities.
1. Introduction
1.1 Report Description
1.2 Research Methodology
1.2.1 Data Mining
1.2.2 Market Modeling and Forecasting
1.2.3 Data Validation
1.2.4 Industry Analysis
2. Market Dashboard
Market Share Analysis
Competitive Benchmarking
Pricing Trends
Recent Developments
3. Market Overview
3.1 Market Definition and Scope
3.2 Market Segmentation
3.2.1 By Treatment Types
3.2.2 By Patient Demographics
3.2.3 By Distribution Channels
3.2.4 By Therapeutic Applications
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.3.4 Challenges
4. United States Bacterial Pneumonia Market by Treatment Types
4.1 Introduction
4.2 Market Size and Growth Rate by Treatment Types (2024–2030)
4.2.1 Chemotherapy
4.2.1.1 Induction Phase
4.2.1.2 Consolidation Phase
4.2.1.3 Maintenance Phase
4.2.2 Targeted Therapies
4.2.2.1 Tyrosine Kinase Inhibitors
4.2.2.2 Antibody-Drug Conjugates
4.2.2.3 Others
4.2.3 Immunotherapies
4.2.3.1 CAR-T Therapy
4.2.3.2 Monoclonal Antibodies
5. United States Bacterial Pneumonia Market by Patient Demographics
5.1 Introduction
5.2 Market Size and Growth Rate by Patient Demographics (2024–2030)
5.2.1 Children
5.2.1.1 Infants
5.2.1.2 Toddlers and Young Children
5.2.2 Adults
5.2.2.1 Young Adults
5.2.2.2 Seniors
6. United States Bacterial Pneumonia Market by Distribution Channels
6.1 Introduction
6.2 Market Size and Growth Rate by Distribution Channels (2024–2030)
6.2.1 Hospital Pharmacies
6.2.1.1 Tertiary Care Centers
6.2.1.2 Pediatric Units
6.2.2 Retail Pharmacies
6.2.2.1 Local Pharmacies
6.2.2.2 Chain Pharmacies
6.2.3 Online Pharmacies
7. United States Bacterial Pneumonia Market by Therapeutic Applications
7.1 Introduction
7.2 Market Size and Growth Rate by Therapeutic Applications (2024–2030)
7.2.1 First-Line Treatment
7.2.1.1 Chemotherapy-Only Regimens
7.2.1.2 Targeted Therapies
7.2.2 Relapse or Refractory Pneumonia
7.2.2.1 CAR-T Therapies
7.2.2.2 Experimental Treatments
8. Competitive Landscape
8.1 Company Profiles
8.1.1 Amgen Inc. (United States)
Business Overview
Product Portfolio
Strategic Developments
Financial Overview
8.1.2 Novartis AG (Switzerland)
8.1.3 Pfizer Inc. (United States)
8.1.4 Gilead Sciences (United States)
8.1.5 Kite Pharma (United States)
8.1.6 Takeda Pharmaceutical Company (Japan)
8.1.7 Bristol-Myers Squibb (United States)
8.1.8 Jazz Pharmaceuticals (Ireland)
8.1.9 AbbVie Inc. (United States)
8.1.10 Sanofi (France)
8.1.11 Autolus Therapeutics (United Kingdom)
8.1.12 Cellectis (France)
8.1.13 Allogene Therapeutics (United States)
8.1.14 Celgene Corporation (United States)
8.1.15 Eli Lilly and Company (United States)
9. Conclusion and Recommendations
10. Appendix
10.1 List of Tables
Table United States Bacterial Pneumonia Market Size by Treatment Types (2024–2030)
Table Chemotherapy Market Size by Sub-type (2024–2030)
Table Targeted Therapies Market Size by Sub-type (2024–2030)
Table Immunotherapies Market Size by Sub-type (2024–2030)
Table Market Size by Patient Demographics (2024–2030)
Table Children Market Size by Age Group (2024–2030)
Table Adults Market Size by Age Group (2024–2030)
Table Market Size by Distribution Channels (2024–2030)
Table Hospital Pharmacies Market Size by Sub-type (2024–2030)
Table Retail Pharmacies Market Size by Sub-type (2024–2030)
Table Market Size by Therapeutic Applications (2024–2030)
Table First-Line Treatment Market Size by Sub-type (2024–2030)
Table Refractory Treatment Market Size by Sub-type (2024–2030)
Table Financial Overview of Key Companies
10.2 List of Figures
Figure Market Size and Growth Rate by Treatment Types (2024–2030)
Figure Chemotherapy Market Growth Rate by Sub-type (2024–2030)
Figure Targeted Therapies Growth Rate by Sub-type (2024–2030)
Figure Immunotherapies Growth Rate by Sub-type (2024–2030)
Figure Market Size by Patient Demographics (2024–2030)
Figure Children Segment Growth Rate (2024–2030)
Figure Adult Segment Growth Rate (2024–2030)
Figure Market Size by Distribution Channels (2024–2030)
Figure Hospital Pharmacies Growth Rate by Sub-type (2024–2030)
Figure Retail Pharmacies Growth Rate by Sub-type (2024–2030)
Figure Market Size by Therapeutic Applications (2024–2030)
Financial Figures for Key Players (Amgen, Pfizer, etc.)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States Bacterial Pneumonia Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of CANOMAD syndrome Market for the past year and forecasts for the next six years. United States Growth Hormone Deficiency Marketsize is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States Growth Hormone Deficiency Marketcategories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United States Growth Hormone Deficiency Marketfrom different application industries in different regions.
